RxNorm 2474241
naxitamab-gqgk 4 MG/ML [Danyelza]
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 2474241 unique identifier include: naxitamab-gqgk 4 MG/ML [Danyelza] (12531985).
RxNorm Atom ID: 12531985 - Semantic Branded Drug Component
naxitamab-gqgk 4 MG/ML [Danyelza]
- RXCUI:
- 2474241 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12531985 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- naxitamab-gqgk 4 MG/ML [Danyelza] - Description of concept identifier
- Term Type (TTY):
- SBDC - Term type in source with name and description
- Term Type Name:
- Semantic Branded Drug Component - Name of term type in source
- Term Type Description:
- Ingredient + Strength + Brand Name - Description of term type in source
- Code:
- 2474241 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Naxitamab-gqgk Injection
Naxitamab-gqgk injection is used in combination with another medication in adults and children 1 year of age and older to treat neuroblastoma (a cancer that begins in nerve cells) in the bone or bone marrow that has returned or that did not respond to a previous treatment, but who have responded to other treatments. Naxitamab-gqgk injection is in a class of medications called monoclonal antibodies. It works by killing cancer cells.
[Learn More]
* Please review the disclaimer below.